Factor IX Treatment & Management
- Author: Robert A Schwartz, MD, MPH; Chief Editor: Emmanuel C Besa, MD more...
Medical Care
A review of the global experience with plasma derived factor IX (pdFIX; Immunine and Mononine) products or rFIX showed that the 2 types of products are comparable with regards to reliability, tolerability, and clinical efficacy, with rare occurrences of serious adverse effects in either product. The major difference was variable pharmacokinetics, with a similar half-life but an approximately 25-30% lower in vivo recovery after rFIX, particularly in younger children (in children < 16 y according to Poon, 2001[14] ; in children < 15 y according to Roth, 2001[15] ).
Data obtained from a survey of several French hemophilia centers and presented at the International Society of Thrombosis and Haemostasis meeting in July 2001 showed an average recovery of 61% for rFIX use versus 85% for pdFIX. Initial dosing of FIX for both inpatient and outpatient treatment is on the basis of standard guidelines (Indiana Hemophilia & Thrombosis Center).
Worldwide, only 25 patients with allergic reactions have been reported to the manufacturer of rFIX, with mild-to-moderate skin and respiratory reactions in most of the patients. Of 5 patients with anaphylaxis, some developed an inhibitor, and no fatalities were reported. Three thrombotic events were reported, of which 2 were catheter related and the third patient, aged 14 years, had a transient ischemic event but did well when continued on rFIX. Seventeen of 4500 patients had red cell agglutination when blood was withdrawn into the catheter or syringe containing rFIX; this practice must be avoided.
Although many reports exist of the successful use of different continuous infusion regimens of FIX, ongoing data collection and studies will allow development of a standardized regimen in the future. Potential benefits include the ability to mimic the physiologic state and reduction in product usage, providing much-needed economic savings.
Both pdFIX and rFIX are highly effective, but rFIX is believed to be free of blood-borne pathogens.
In children who are starting therapy for the first time or in persons with hemophilia who are HIV negative, recombinant products are used whenever possible because of their presumed higher viral safety. Note that approximately 25% of the lots of human albumin containing first-generation recombinant factor VIII (rFVIII) concentrates have been found to be positive for transfusion transmitted virus (TTV) from contaminated human serum albumin. All of the second-generation rFVIII preparations (free from human albumin) were negative for the virus.[16]
It is important to understand the pharmacokinetics of factor IX.[17] Factor IX in vivo recovery is also relatively short possibly due to its reversible binding to endothelium and possibly to platelets. There is considerable pharmacokinetic variability of factor IX between products (particularly between plasma-derived factor IX and recombinant factor IX), and between individuals.
- Factor replacement in patients with hemophilia B should be guided by an experienced hematologist who is familiar with treating patients with coagulation disorders.
- The location and severity of bleeding determine the dose and duration of factor replacement therapy. Highly purified FIX concentrates (monoclonal antibody purified FIX or rFIX) are now available (first dose: 20-80 IU/kg depending on FIX level necessary to treat the specific clinical condition).
- Approximately 50% of the first dose is administered approximately every 24 hours to maintain the initial level of FIX.
- If therapy is to last for more than 2 days or is occurring for the first time, FIX levels should be obtained immediately after the first dose, with a subsequent trough level taken to determine appropriate dose and frequency of replacement therapy based on in vivo response to a specific product. Children and surgical patients require closer monitoring of FIX levels because of known variable pharmacokinetics and a lack of a steady state, respectively.
- Preservation of the hemostatic plug formed in the presence of adequate levels of FIX at the time of surgery (ie, dental extraction) can be achieved by inhibiting fibrinolysis with EACA or tranexamic acid (Cyklokapron) administered orally or IV as needed. Inhibitors of fibrinolysis, such as EACA or tranexamic acid, can be used in combination with factor replacement to prevent bleeding from mucosal sites, including after dental extractions or sinus surgery. Following the surgical procedure, the drugs are continued, then tapered as the wound heals. Such treatment allows use of a single dose to prevent bleeding from minor procedures. However, fibrinolytic inhibitors are not of value in the treatment of hemarthroses or deep-seated bleeding. The prolonged use of fibrinolytic inhibitors in joint and deep hematomas can lead to persistence (lack of absorption) of the clot with negative consequences.
- A dose of EACA, 5 g orally or IV, is administered immediately before the surgical procedure along with a dose of FIX, followed by 1 g per hour postoperatively until the decision is made to taper the dose over the next 5 days.
- Tranexamic acid can be administered in a dose of 1.5 g every 6-8 hours for 5 days; this drug is not available in the United States.
- Administration of these fibrinolytic inhibitors is contraindicated in patients with hematuria who are receiving or have recently received FIX product because of the risk of an acute persistent thrombus obstructing the ureters and causing acute hydronephrosis.
- Nonnarcotic and narcotic analgesics are used to relieve pain. Narcotic analgesics are used to manage severe acute pain, such as occurs with joint bleeding or perioperatively. Chronic persistent pain of chronic joint disease can be difficult to manage. Ideally, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in patients with a bleeding disorder because the addition of platelet dysfunction caused by the drugs can potentiate bleeding. However, because of the persistent demand by individuals with hemophilia, cyclooxygenase 2 (COX-2) inhibitors are being tried with caution because of a lack of efficacy of nonnarcotic pain relievers in severe arthritis. Use of NSAIDs by individuals with hemophilia has increased in an attempt to relieve the severe joint pain of chronic arthritis.
- Several approaches to gene therapy have been undertaken in treating patients with hemophilia B or A with severe deficiency. Basal levels of 5-10% significantly ameliorate bleeding in persons with severe hemophilia.
- The most successful and least toxic method of introducing the gene remains to be determined. The use of an attenuated adenoviral vector, although associated with high short-term expression in a canine model of hemophilia, led to liver toxicity, thrombocytopenia, and an antibody to the factor due to an immunologic response to the vector.
- An additional question is the appropriate in vivo–vector dose to be administered; evidence is emerging for the need for a minimum threshold dose.
- Short-term correction resulting from high gene expression in the neonatal period following in utero injection of an adenoviral murine vector has been accomplished with FVIII.
- Use of a parvovirus, use of transduced endothelial cells, or the possibility of cutaneous gene therapy are being explored in animal models and in humans.
- Development of antibodies to replaced proteins is a major problem, and the possibility of using CTLA4-Ig to block T-cell function to prevent antibody response has been explored in murine models of hemophilia A.
- Several possible approaches to gene therapy include ex vivo gene therapy, in which the cells to be injected are modified to secrete FIX or FVIII and then are reimplanted into the recipient, and in vivo gene therapy, in which cells modified to secrete the missing factor are packaged in immunoprotected devices and implanted in recipients.
- Gene therapy with a variety of vectors has been tested in humans, with the most successful method still to be determined. Gene therapy studies were halted following the death of a patient treated for a metabolic disorder. Reevaluation of the type of vector, dose, route, and toxicity of the different approaches to gene therapy was undertaken. Oligonucleotides possibly can be used in vivo to correct point mutations. Advantages and disadvantages of several approaches to gene therapy in individuals with hemophilia and other patients have been updated in two recent publications.[18, 19]
- Gene therapy with viral-based vectors has had efficacy limited by immune responses against the viral components.[20]
Gene therapy remains promising.[7, 21, 20] In humans, one hemophilia B patient achieved 10% of normal activity after liver-directed gene therapy with a single-stranded adeno-associated virus vector expressing human factor IX, but expression fell at 1 month. Thus, gene therapy may be viewed as successful in a patient with hemophilia B, but expression was unstable probably due to an immune response. Abrogating immune responses may be the next important hurdle for achieving long-lasting gene therapy.
Surgical Care
Appropriate preoperative evaluation includes an aPTT mixing test after incubation for 1-2 hours at 37°C with pooled normal plasma to exclude an inhibitor, followed by administration of an appropriate preoperative dose of concentrate, followed by appropriate postoperative treatment.
Recent small studies have established the efficacy of using lower than usually recommended doses of FIX concentrate, administered as an intermittent bolus infusion after major surgical procedures. Preoperatively, FIX was used in a dose of 77 U/kg to achieve a presurgical level of 107% (range 50-104%). Between days 1 and 3 after surgery, an average of 23 U/kg/d was used with an average trough value of FIX of 34% (range 11-52%). After day 4, an average of 18 U/kg/d of FIX was used until wound healing occurred. This resulted in a significant reduction in overall factor used without hemostatic inadequacy. Such data underscore the importance of defining the least amount of factor replacement necessary to obtain and maintain adequate hemostasis.
- The use of fibrin sealants (ie, fibrin glue, fibrin adhesive), which consist of fibrinogen and thrombin with variable incorporation of factor XIII (FXIII) and fibrinolytic inhibitors, has helped improve surgical hemostasis markedly, thereby permitting necessary high-risk surgery (eg, pseudotumors, surgery in patients with hemophilia with inhibitors). This technology reduces or eliminates the need for prolonged replacement using expensive clotting factor concentrates and may eliminate or reduce the need for hospitalization. In total, the measures result in improved quality of life in patients with hemophilia, while achieving a reduction in medical care costs. Bovine thrombin used in these preparations may result in development of inhibitors to several factors, including thrombin and FV, as it has in other postoperative states.
- Warn patients to avoid any antiplatelet drug starting 1 week prior to surgery and in the immediate postoperative period to minimize the risk of bleeding.
- The use of ice packs at surgical sites may be beneficial to reduce the size of the surgical site hematoma.
Consultations
- Hematologist, including general medical evaluation
- Orthopedist
- Physical therapist
- Dentist
- Surgeon
- Social worker
- Psychiatrist, particularly in the management of HIV-related issues[22]
- Geneticist for genetic testing and counseling for family members
Diet
Encourage a generally healthy and nutritious diet.
Activity
- Activity recommendations depend on such factors as joint disease and resolution of bleed into joints and muscles.
- Appropriate use of physical therapy is advised.
Chavali S, Sharma A, Tabassum R, Bharadwaj D. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX. Proteins. Apr 7 2008;[Medline].
Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. Oct 2009;102(4):634-44. [Medline].
Smith SB, Gailani D. Update on the physiology and pathology of factor IX activation by factor XIa. Expert Rev Hematol. Oct 2008;1(1):87-98. [Medline].
Bauer KA, Kass BL, ten Cate H, et al. Factor IX is activated in vivo by the tissue factor mechanism. Blood. Aug 15 1990;76(4):731-6. [Medline].
Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. Jun 2001;85(6):958-65. [Medline].
Roberts HR, Monroe DM III, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Beutler E, Lichtman M, Coller B, et al, eds. Williams Hematology. 2001. 6th ed. New York, NY: McGraw-Hill Professional; 2001:1409-34.
Zdziarska J, Chojnowski K, Klukowska A, Letowska M, Mital A, Podolak-Dawidziak M, et al. Therapeutic properties and safety of recombinant factor VIII and factor IX. Pol Arch Med Wewn. Jun 2009;119(6):403-9. [Medline].
Quadros L, Ghosh K, Shetty S. A common G10430A mutation (Gly 60 Ser) in the factor IX gene describes the presence of moderate and mild hemophilia B in the majority of the Gujarati population. Ann Hematol. May 2007;86(5):377-9. [Medline].
Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol. Feb 2001;112(2):264-74. [Medline].
Kulkarni R, Lusher JM, Henry RC, Kallen DJ. Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemop. Haemophilia. Nov 1999;5(6):410-5. [Medline].
Sidonio RF Jr, Gunawardena S, Shaw PH, Ragni M. Predictors of von Willebrand disease in children. Pediatr Blood Cancer. Jan 11 2012;[Medline].
Christophe OD, Lenting PJ, Cherel G, et al. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. Blood. Sep 1 2001;98(5):1416-23. [Medline].
Park CH, Seo JY, Kim HJ, Jang JH, Kim SH. A diagnostic challenge: mild hemophilia B with normal activated partial thromboplastin time. Blood Coagul Fibrinolysis. Jun 2010;21(4):368-71. [Medline].
Poon MC. Clotting Factor IX in Hemophilia B: Global Experience. Paper presented at: XVIII Congress of the International Society on Thrombosis and Haemostasis. July 6-12, 2001;Paris, France.
Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. Dec 15 2001;98(13):3600-6. [Medline].
Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood. Oct 15 2001;98(8):2571-3. [Medline].
Poon MC. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia. Nov 2006;12 Suppl 4:61-9.
Hedner U, Ginsburg D, Lusher JM, High KA. Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. Hematology (Am Soc Hematol Educ Program). 2000;241-65.
Coukos G, Rubin SC. Gene therapy for ovarian cancer. Oncology (Huntingt). Sep 2001;15(9):1197-204, 1207; discussion 1207-8. [Medline].
Fewell JG. Factor IX gene therapy for hemophilia. Methods Mol Biol. 2008;423:375-82. [Medline].
Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol. Sep 2006;13(5):301-7. [Medline].
Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. Dec 12 2001;286(22):2857-64. [Medline].
Lin CN, Kao CY, Miao CH, Hamaguchi N, Wu HL, Shi GY, et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost. May 21 2010;[Medline].
Di Bisceglie AM. SEN and sensibility: interactions between newly discovered and other hepatitis viruses?. Lancet. Dec 8 2001;358(9297):1925-6. [Medline].
Rigas B, Hasan I, Rehman R, et al. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet. Dec 8 2001;358(9297):1961-2. [Medline].
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. Jul 5 2001;345(1):41-52. [Medline].
MediView. Recombinant therapy enhances safety and quality of life for hemophilia patients. Paper presented at: 53rd Annual Meeting of the National Hemophilia Foundation. November 16, 2001:Nashville, Tennessee.
Senior K. New variant CJD fears threaten blood supplies. Lancet. Jul 28 2001;358(9278):304. [Medline].
Feuerstein GZ, Nichols AJ, Church WR. Novel murine monoclonal antifactor IX/IXa (BC2) is a potent anticoagulant with "self limiting" inhibition of hemostasis. Circulation. 1997;96:142.
Kjalke M, Monroe DM, Hoffman M, et al. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost. Oct 1998;80(4):578-84. [Medline].
Spanier TB, Oz MC, Minanov OP, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg. May 1998;115(5):1179-88. [Medline].
Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost. Feb 2012;38(1):79-94. [Medline].
Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. Jun 16 1995;270(24):14477-84. [Medline].
Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. Sep 15 1996;88(6):2093-100. [Medline].
Bouma BN, von dem Borne PA, Meijers JC. Factor XI and protection of the fibrin clot against lysis--a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost. Jul 1998;80(1):24-7. [Medline].
Brooks M. A review of canine inherited bleeding disorders: biochemical and molecular strategies for disease characterization and carrier detection. J Hered. Jan-Feb 1999;90(1):112-8. [Medline].
Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. Nov 15 1996;88(10):3815-23. [Medline].
Economides DL, Kadir RA, Lee CA. Inherited bleeding disorders in obstetrics and gynaecology. Br J Obstet Gynaecol. Jan 1999;106(1):5-13. [Medline].
The fibrinolytic system and thrombolytic agents. In: Bachmann F, ed. Fibrinolytics and Antifibrinolytics. New York, NY: Springer-Verlag; 2001:3-15.
Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia. Sep 1999;5 Suppl 3:11-7. [Medline].
Hoots K, Canty D. Clotting factor concentrates and immune function in haemophilic patients. Haemophilia. Sep 1998;4(5):704-13. [Medline].
Kasper CK, Costa E, Silva M. Registry of Clotting Factor Concentrates. World Federation of Hemophilia;1998:1-8.
Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. Dec 1998;80(6):912-8. [Medline].
Knobe KE, Persson KE, Sjörin E, Villoutreix BO, Ljung RC. Functional analysis of the factor IX epidermal growth factor-like domain mutation Ile66Thr associated with mild hemophilia B. Pathophysiol Haemost Thromb. 2006;35(5):370-5. [Medline].
Lillicrap D. Molecular diagnosis of inherited bleeding disorders and thrombophilia. Semin Hematol. Oct 1999;36(4):340-51. [Medline].
Mosnier LO, von dem Borne PA, Meijers JC, et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. Nov 1998;80(5):829-35. [Medline].
Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. Feb 15 2000;95(4):1324-9. [Medline].
Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia. Jul 1999;5(4):266-9. [Medline].
Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. Nov 1995;96(5):2534-8. [Medline].
Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. Nov 1998;80(5):773-8. [Medline].
Srivastava A, Chandy M, Sunderaj GD, et al. Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia. Haemophilia. Nov 1998;4(6):799-801. [Medline].
Tedgard U, Ljung R, McNeil TF. Reproductive choices of haemophilia carriers. Br J Haematol. Aug 1999;106(2):421-6. [Medline].
Teitel JM. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations. Haemophilia. Sep 1999;5 Suppl 3:43-9. [Medline].
Thomson AR. Molecular biology of F IX. In: Colman RW, George JN, Hirsh J, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott-Raven Pub; 2001:123-34.
Tock B, Drohan W, Hess J, et al. Haemophilia and advanced fibrin sealant technologies. Haemophilia. Jul 1998;4(4):449-55. [Medline].
Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. Jan-Feb 1997;19(1):23-7. [Medline].
Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood. Jul 1 1992;80(1):25-8. [Medline].
| Severity | Functional FIX Levels, % | Bleeding and Hemarthroses |
| Severe | ≤ 1 | Lifelong spontaneous hemorrhages and hemarthroses starting in infancy |
| Moderate | 2-5 | Hemorrhage secondary to minor trauma or surgery; occasional spontaneous hemarthrosis |
| Mild | 6-25 | Hemorrhage secondary to trauma, surgery, or precipitated by the use of drugs such as nonsteroidal anti-inflammatory drugs |
| Type of Hemorrhage | Desired FIX Activity, % of Normal | Duration of Therapy, Days |
| Minor - Uncomplicated hemarthroses superficial large hematomas | 20-30 | 1-2 |
| Moderate - Hematoma with dissection Oral/mucosal hemorrhages and epistaxis hematuria* | 25-50 | 3-7 (2-5 in oral hemorrhages) |
| Dental extraction(s)* | 50-100 | 2-5 |
| Major - Pharyngeal/retropharyngeal, retroperitoneal, GI tract bleeding, CNS bleeding surgery | ~100 until bleeding is controlled; then taper to minimum required to prevent rebleed | 7-10 (5-10 in oral hemorrhages) |
| *Concomitant administration of EACA or tranexamic acid (both fibrinolytic inhibitors) can help reduce the dose of clotting factor replacement required to treat such bleeds. | ||

